Skip to content

Own blood product injection into joint and in bone in Osteoarthritis Knee

Role of Intra-articular and Intra-osseous injections of Platelet Rich Plasma in OA Knee - IA and IO injections of PRP in OA Knee

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/04/018613
Enrollment
50
Registered
2019-04-15
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M170- Bilateral primary osteoarthritis of knee

Interventions

Intervention1: Intra-articular and intra-osseous PRP Group (IA,IO-PRP): Under aseptic conditions, One PRP (8ml) intraarticular injection and two PRP intraosseous injections (5ml each ) will be given u

Sponsors

All India Institute of Medical Sciences Bhubaneswar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients aged 40-65 years, who are able to walk with a painful knee and fulfilled the criteria for knee OA of the medial femorotibial joint, as defined by the American College of Rheumatology (ACR). 2. Persisting Knee Pain due to OA Knee (Grade II/III, according to the radiological classification of knee OA defined by Kellgren and Lawrence) 3. Pain of at least 20 mm on a 0-100mm VAS when asked: â??how painful is your knee during level walking?â?? 4. If both knees involved, participants choose one or both knees to be treated. 5. Willing to participate in all assessment

Exclusion criteria

Exclusion criteria: 1) Severe OA Knee (Grade IV, according to Kellgren and Lawrence classification) 2) Haemoglobin level 3) Inflammatory or post-infectious knee arthritis 4) History of prior knee replacement repair 5) Prior fracture of the knee joint 6) Any Knee injection within 3 months 7) Daily use of opioid medication 8) Coexisting Backache, other chronic pain disorder 9) Body mass index (BMI) greater than 40 kg/m2 10) Blood disorders, hematological, cardiac, hepatic or renal disorders. 11) Patients who had received either an oral, topical or intra-articular steroid during the four weeks before the study pregnancy 12) Co-morbidity severe enough to prevent participation in the study protocol including at-home exercise or attendance at scheduled injection appointments.

Design outcomes

Primary

MeasureTime frame
Visual analogue pain Score (0-10cm) Timepoint: 0 month (V1), 1.5 months (V2), 3 months (V3)

Secondary

MeasureTime frame
KOOS questionnaire (0-100) Range of motion of affected knee jointTimepoint: 0 month, 1.5 months, 3 months

Countries

India

Contacts

Public ContactApurba Barman

AIIMS Bhubaneswar

apurvaa23@gmail.com9438884211

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026